Summary
ZIOPHARM Oncology, Inc. (ZIOPHARM), formerly EasyWeb, Inc. is a biotechnology company that discovers and develops cancer therapies. The company develops novel gene expression, control and cell technologies to deliver safe, effective and scalable cell-based therapies for the treatment of cancer and graft-versus-host-disease (GvHD). It offers engineering techniques and multi-genic gene programs to develop next-generation patient- and donor-derived adoptive cellular therapies. ZIOPHARM’s pipeline products include Ad-RTS-IL-12 and CAR/Cytokine Products. The company’s technology platforms include RheoSwitch therapeutic system, UltraVector, adoptive cell therapy, ActoBiotics, AttSite Recombinases and Leap among others. Its products and technologies are used in the treatment of hematologic malignancies, solid tumors and graft-versus-host-disease. ZIOPHARM is headquartered in Boston, Massachusetts, the US.
ZIOPHARM Oncology, Inc. (ZIOP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
                     
                                   '
                        
Table of Contents
Table of Contents  2
List of Tables  3
List of Figures  4
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016  5
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016  6
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016  7
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016  8
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016  9
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deal Details  10
Partnerships  10
Intrexon Enters into Co-Development Agreement with Ziopharm Oncology  10
Ziopharm Expands Co-Development Agreement with Intrexon  11
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology  12
Ziopharm Oncology Plans To Enter Into Co-Marketing Agreement For Palifosfamide  14
ZIOPHARM Oncology Enters Into Co-Development Agreement With Intrexon  15
Licensing Agreements  17
Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center  17
Ziopharm Amends Licensing Agreement with Solasia Pharma for Darinaparsin  19
ZIOPHARM Oncology Enters Into Licensing Agreement With Solasia Pharma For Darinaparsin  21
Equity Offering  23
Ziopharm Oncology Completes Exercise of Over-Allotment Option of Public Offering of Shares for USD100.6 Million  23
Ziopharm Oncology Completes Public Offering Of Shares For US$50 Million  25
ZIOPHARM Oncology Completes Public Offering Of Common Stock For US$50 Million  26
ZIOPHARM Oncology Completes An Underwritten Public Offering Of US$63.5 Million  28
ZIOPHARM Oncology Completes Underwritten Public Offering For US$35 Million  30
ZIOPHARM Oncology, Inc. - Key Competitors  32
Key Employees  33
Locations And Subsidiaries  34
Head Office  34
Appendix  35
Methodology  35
About GlobalData  35
Contact Us  35
Disclaimer  35
List of Tables
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Key Facts, 2015  1
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016  5
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016  6
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016  7
ZIOPHARM Oncology, Inc., Deals By Therapy Area, 2010 to YTD 2016  8
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016  9
Intrexon Enters into Co-Development Agreement with Ziopharm Oncology  10
Ziopharm Expands Co-Development Agreement with Intrexon  11
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology  12
Ziopharm Oncology Plans To Enter Into Co-Marketing Agreement For Palifosfamide  14
ZIOPHARM Oncology Enters Into Co-Development Agreement With Intrexon  15
Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center  17
Ziopharm Amends Licensing Agreement with Solasia Pharma for Darinaparsin  19
ZIOPHARM Oncology Enters Into Licensing Agreement With Solasia Pharma For Darinaparsin  21
Ziopharm Oncology Completes Exercise of Over-Allotment Option of Public Offering of Shares for USD100.6 Million  23
Ziopharm Oncology Completes Public Offering Of Shares For US$50 Million  25
ZIOPHARM Oncology Completes Public Offering Of Common Stock For US$50 Million  26
ZIOPHARM Oncology Completes An Underwritten Public Offering Of US$63.5 Million  28
ZIOPHARM Oncology Completes Underwritten Public Offering For US$35 Million  30
ZIOPHARM Oncology, Inc., Key Competitors  32
ZIOPHARM Oncology, Inc., Key Employees  33
List of Figures
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016  1
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016  1
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016  1
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016  1
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016  5
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016  6
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016  7
ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016  8